HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter financial results for the period ended March 31, 2026, and provide updates on key growth initiatives. The call will cover the company's limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection capabilities, and artificial intelligence programs.
The announcement underscores HeartBeam's progress in advancing its 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company's platform is designed to collect ECG signals in three dimensions from a cable-free device, synthesizing them into a standard 12-lead ECG. This technology aims to enable physicians to identify cardiac health trends and acute conditions outside of medical facilities, potentially redefining cardiac health management.
HeartBeam holds over 20 issued patents related to its technology. The company's focus on portable, actionable cardiac intelligence positions it to address significant unmet needs in heart disease detection and monitoring. The upcoming call will provide investors and stakeholders with insights into commercial adoption, product development timelines, and strategic direction.
For more details on the conference call and to access the full press release, visit https://ibn.fm/yN939. Additional information about HeartBeam's cleared indications for use is available at https://www.heartbeam.com/indications. The latest news and updates on HeartBeam can be found in the company's newsroom at https://nnw.fm/BEAT.
